ClinicaliQ Trial Snapshot
- Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) — Recruiting • Phase III • Respiratory / COPD / Asthma • NCT06961214.
- What is being tested: Depemokimab, a biologic therapy administered as an add-on treatment, is being evaluated for efficacy and safety in patients with uncontrolled moderate to severe COPD characterised by type 2 inflammation.
- Patient eligibility overview: Adults with moderate to severe COPD who remain symptomatic despite standard treatment and demonstrate evidence of type 2 inflammatory markers are eligible for inclusion in this extended-duration treatment trial.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Eligibility Snapshot
- : * Participants must be greater than or equal to (>=) 40 to less than or equal to (30 percent (%) and =10 at Visit 1 * Smoking status: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years. * Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1 * Body mass index (BMI) >=16 kilogram per square meter (kg/m^2) * Male and eligible female participants
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.